Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
- The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
60 Degrees Pharmaceuticals IncAbhelix LLC
Abivax SA
ADMA Biologics Inc
Advac LLC
Advagene Biopharma Co Ltd
AIM Vaccine Co Ltd
Airway Therapeutics Inc
AlloVir Inc
Amniotics AB
Anima Biotech Inc
Aposense Ltd
Aridis Pharmaceuticals Inc
Artificial Cell Technologies Inc
Ascletis Pharma Inc
Asterivir SA
AstraZeneca Plc
Atea Pharmaceuticals Inc
Atriva Therapeutics GmbH
Auro Vaccines LLC
AVM Biotechnology LLC
Baiya Phytopharm Co Ltd
Beijing Advaccine Biotechnology Company Ltd
Beijing Health Guard Biotechnology Inc
Beijing Tricision Biotherapeutics Inc
Bill & Melinda Gates Medical Research Institute
BioComo Inc
Biological E Ltd
Bioxytran Inc
Blue Lake Biotechnology Inc
BravoVax Co Ltd
Calder Biosciences Inc
Celestial Therapeutics Inc
Centre for Drug Design and Discovery
Changchun Bcht Biotechnology Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chengdu WestGene Biopharma Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Codagenix Inc
ConserV Bioscience Ltd
Curevac NV
Daiichi Sankyo Co Ltd
Decoy Therapeutics Inc
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperovax Inc
Eucure (Beijing) Biopharma Co Ltd
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Foundation For Neglected Disease Research
Georgia State University
Ghent University
Gilead Sciences Inc
GSK plc
HanaVax Inc
Heartland Vaccines LLC
HES-SO Valais-Wallis
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immorna Hangzhou Biotechnology Co Ltd
Imophoron Ltd
IMV Inc
Inhalon Biopharma Inc
Inovio Pharmaceuticals Inc
Inventprise LLC
InvisiShield Technologies Ltd
iX Biopharma Ltd
Johnson & Johnson
KARE Biosciences Inc
Kidswell Bio Corp
King Saud University
Mabxience Holding SL
Mapp Biopharmaceutical Inc
McMaster University
Meissa Vaccines Inc
Merck & Co Inc
MicroQuin Ltd
Moderna Inc
NanoViricides Inc
National Taiwan University
NeuClone Pty Ltd
Neuracle Science Co Ltd
NextCell Pharma AB
Novavax Inc
Oita University Institute of Advanced Medicine Inc
Pfizer Inc
Pinetree Therapeutics Inc
Pneumagen Ltd
Poolbeg Pharma Plc
Posvax Co Ltd
Prime Vector Technologies GmbH
Primmune Therapeutics Inc
Prosetta Biosciences Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
ReAlta Life Sciences Inc
Red Queen Therapeutics Inc
RedHill Biopharma Ltd
Research Institute of Influenza
Riboscience LLC
RNAimmune Inc
Ruiyang (Suzhou) Biotechnology Co Ltd
Sagimet Biosciences Inc
Sanofi
Sciogen LLC
Sciwind Biosciences Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Ark Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Signia Therapeutics
SK Bioscience Ltd
Stemirna Therapeutics Ltd
Suzhou Abogen Biosciences Co Ltd
Suzhou Vigonvita Life Sciences Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
TechnoVax Inc
The Chinese University of Hong Kong
The National Institute of Allergy and Infectious Diseases
The University of Manchester
Trimunocor Ltd
TrippBio Inc
UMass Chan Medical School
University of Georgia
University of Pittsburgh
University of Queensland
Uvax Bio LLC
Vanderbilt University
Vault Pharma Inc
Vaxart Inc
Vaxxel SAS
Vernagen Inc
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
VLP Biotech Inc
Walvax Biotechnology Co Ltd
X4 Pharmaceuticals Inc
XBiotech Inc
Zhengzhou University
Zhuhai Trinomab Biotechnology Co Ltd